Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Though forward …??

<< Previous

Bullboard Posts

Next >>

Comment by Quentin30on Nov 05, 2024 3:41pm

91 Views

Post# 36297600

RE:Though forward …??

I think you mean "fund" the mBC product trial... and just to be clear accelerated approval is a MINIMUM of 2 years away...

It may be accelerated approval by definition, but by the time it is granted, IF it is granted, 10 years will have elapsed since ONCY was granted a SPA to run a final phase III trial..

Where is Matt he's been missing in action for over 4 months now....

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec